FDA
-
-
-
-
-
-
-
Gilead to acquire Arcellx for $7.8 billion to gain control of cancer therapy
-
-
-
-
-
-
-
Gilead Sciences (GILD) PT Raised to $145 at Truist Securities
-
-
-
-
-
-
-
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
-
-
-
-
-
-
-
GILD presents long-term data on Livdelzi for liver disease treatment
-
-
-
-
-
-
-
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
-
-
-
-
-
-
-
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
-
-
-
-
-
-
-
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

